Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMR Industry Alliance Publishes Manufacturing Standard

Certification Scheme Will Be Published ‘Next Spring’

Executive Summary

The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.

You may also be interested in...



Centrient Hails Milestone For Clean Antibiotic Production

Centrient has celebrated passing a “significant milestone in the clean production of antibiotics” after meeting Predicted No Effect Concentration discharge targets set by the AMR Industry Alliance across its entire oral antibiotics product range.

Sandoz And Ares Extend AMR Collaboration Ahead Of Next Phase

With plans to enable genomic surveillance for antimicrobial resistant pathogens using Ares’ next-generation sequencing and bioinformatics technologies, the OpGen subsidiary and Sandoz have shaken hands on an extension to their initial master services agreement.

Lack Of Incentives Threatens AMR Investment

The AMR Industry Alliance’s 2021 progress report has found that the life sciences industry is helping to shape a positive future outlook in the fight against antimicrobial resistance despite supply-chain disruptions for generics firms, but continued cross-sector collaborations along with policy and regulatory changes toward a more sustainable marketplace are needed.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel